FDA puts rosiglitazone post-marketing trial on hold

BMJ. 2010 Jul 26:341:c4017. doi: 10.1136/bmj.c4017.
No abstract available

Publication types

  • News

MeSH terms

  • Clinical Trials as Topic
  • Humans
  • Hypoglycemic Agents / adverse effects*
  • Rosiglitazone
  • Safety-Based Drug Withdrawals*
  • Thiazolidinediones / adverse effects*
  • United States
  • United States Food and Drug Administration

Substances

  • Hypoglycemic Agents
  • Thiazolidinediones
  • Rosiglitazone